Tests Myfortic to prevent immune sensitization after islet transplant loss in type 1 diabetes
Tests Myfortic in adults with type 1 diabetes whose islet transplant was lost.
Key facts
- Who runs it
- Rodolfo Alejandro
- Where
- Miami, United StatesSee the site
- Trial code
- Registry title
- Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- Status
- Recruiting
- People taking part
- 18 people, planned
- Started
- Jan 2009
- Expected to end
- Dec 2028
- Type of study
- Interventional
- Treatments tested
- Myfortic
- Record updated
- 23 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who had at least one islet transplant and have now completely lost the graft. They take Myfortic alone to try to prevent new sensitization (new antibodies against donor tissue).
- Age
- 18 to 70 years
- Sex
- Men and women
- Disease stage
- Complete islet graft loss or rejection, with stimulated C-peptide below 0.3 ng/ml.
- Earlier treatment
- At least one islet transplant. Currently taking immunosuppressive medicines, or stopping them as set by the islet transplant protocol.
- Biomarker or test result
- Stimulated C-peptide below 0.3 ng/ml.
Main reasons for not taking part
- Positive pregnancy test or breast-feeding
- Active infection, including hepatitis B, hepatitis C, HIV or TB
- Any past cancer, except fully removed squamous or basal skin cancer
- PRA of 50% or more, or significant sensitization judged by the investigator
- Active alcohol or substance abuse
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Male and female patients age 18-70 years of age
- Ability to provide written informed consent
- Mentally stable and able to comply with the procedures of the study protocol
- Any subject currently prescribed immunosuppressive medications or discontinuation of immunosuppressive medications indicated as per current protocol of islet transplantation
- History of at least one islet transplant
- Stimulated C-peptide <0.3 ng/ml
Who cannot take part
- Known history of untreated severe hyperlipidemia, obesity, or refractory hypertension
- History of active infection including hepatitis B, hepatitis C, HIV, or TB
- Any history of malignancy except for completely resected squamous or basal skin cell carcinoma
- Evidence of inter-current infection
- Active peptic ulcer disease
- Severe co-existing history of cardiac disease, characterized by a history of any one of these conditions: recent myocardial infarction (within past 6 months), evidence of ischemia on functional cardiac exam within the last year, or left ventricular ejection fraction <30%
- History of persistent elevation of liver function tests. SGOT (AST), SGPT (ALT), alkaline phosphatase or total bilirubin, with values >1.5 times normal upper limits will exclude a patient
- For female participants: Positive pregnancy test or presently breast-feeding
- Known active alcohol or substance abuse
- History on non-adherence to prescribed regimens including immunosuppression
- PRA ≥ 50% or evidence of significant sensitization to be determined at discretion of the investigator
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Where in United States
- Diabetes Research InstituteMiami, United StatesContact: Rodolfo Alejandro, MDTaking people
About the trial
What the trial wants to find out
This is a single-center, prospective, open label study in islet transplant recipients after complete islet graft rejection/loss, defined as stimulated c-peptide ≤0.3 ng/mL.
The group in the trial
- Myfortic treatmentTreatment being tested
Treatment with Myfortic
Treatment: Myfortic
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Myfortic® Monotherapy to Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- Plain-language title
- Tests Myfortic to prevent immune sensitization after islet transplant loss in type 1 diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Criteria questions
- Built from NCT01999361, who can take part
- Publications
- Long-term Persistence of Allosensitization After Islet Allograft Failure.Transplantation, 2021
- Record updated
- 23 March 2026